OptimizeRx initiated with an Equal Weight at Stephens

Stephens initiated coverage of OptimizeRx (OPRX) with an Equal Weight rating and $5.50 price target The firm says the company’s “evolving” direct-to-consumer business model toward self-service may create headline risk to net revenue retention. Stephens still needs clarity on the company’s return to growth and evolution of the business model that “cements OptimizeRx’s place in the value chain.”